Product Description
Linezolid is used to treat infections, including pneumonia, and infections of the skin . Linezolid is in a class of antibacterials called oxazolidinones. It works by stopping the growth of bacteria. (Sourced from: https://medlineplus.gov/druginfo/meds/a602004.html)
Mechanisms of Action: Protein Synthesis Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Belarus, Brazil, China, France, Georgia, India, Kazakhstan, Mexico, Pakistan, Peru, Philippines, Romania, Russia, South Africa, Spain, Ukraine, United States, Unknown Location, Uzbekistan, Vietnam
Active Clinical Trial Count: 12
Highest Development Phases
Phase 3: Bronchitis|Communicable Diseases|Diabetic Foot|Extensively Drug-Resistant Tuberculosis|Fractures, Open|Gram-Positive Bacterial Infections|Mycobacterium Infections|Pneumonia, Bacterial|Pneumonia, Ventilator-Associated|Skin Ulcer|Soft Tissue Infections|Tuberculosis, Multidrug-Resistant|Tuberculosis, Pulmonary|Yaws
Phase 2: Acute Respiratory Distress Syndrome|Febrile Neutropenia
Phase 1: Bacteremia|Community-Acquired Infections|Osteomyelitis|Pneumonia
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| DURATIOM | P3 |
Unknown Status |
Fractures, Open |
2027-12-31 |
|
| DRAMATIC | P2 |
Recruiting |
Tuberculosis, Multidrug-Resistant |
2027-05-01 |
|
| endTB-Q | P3 |
Active, not recruiting |
Mycobacterium Infections|Tuberculosis, Multidrug-Resistant|Communicable Diseases|Gram-Positive Bacterial Infections|Tuberculosis, Pulmonary |
2024-09-01 |
|
| Trep-AByaws | P3 |
Active, not recruiting |
Skin Ulcer|Yaws |
2024-06-20 |